Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer

Prior treatment

• Presence of metallic foreign bodies / implants / prostheses / stimulators etc. inside the body, the possession of which is a contraindication to the MR 3T examination

Other illness

• Known contraindications for the use of radiopharmaceuticals or substances auxiliary (e.g. renal failure and allergy to ingredients in the preparation)
• Treatment for malignant neoplasm not associated with the prostate gland

Age

• Age \<18 years

Other

• Claustrophobia
• Patient size precluding PET / MR examination due to diameter gantry
• Participating in another clinical trial
• Lack of informed consent to participate in the study

• Group 1. Patients with diagnosis or high probability of medium and high prostate cancer according International Society of Urological Pathology (ISUP) risk for whom radical treatment is planned
• Prostate adenocarcinoma confirmed by biopsy and histopathological examination
• Results indicating a moderate RGK (Gleason score 7 or cT2b or PSA 10-20 ng / ml) or high (Gleason score\> 7 or cT2c or PSA\> 20 ng / ml) risk according to ISUP
• Creatinine value allowing for safe PET / MR examination with a contrast agent: creatinine less than or equal to 1.5 times the upper limit of normal, creatinine clearance\> 60 mL / min
• Age ≥18 years
• Signing informed consent to participate in the study
• Pelvic / prostate mpMR examination performed, not earlier than 30 days before inclusion in the study
  • Group 2. Patients with RGK after radical treatment, with biochemical recurrence according to EAU criteria, who are scheduled for further treatment and the result of the imaging / molecular examination may affect change of therapeutic decision:
• Prostate adenocarcinoma confirmed by biopsy and histopathological examination
• After radical treatment
• In patients after radical prostatectomy: with at least two PSA measurements ≥0.2 ng / ml not earlier than after 6-13 weeks after radical prostatectomy or PSA≥0.1 with PSAdt (PSA doubling time) \<3 months PSA on at least two consecutive studies in consecutive last 6 months before qualification (last determination within 6 weeks before qualification) Or
• In patients after radical radiotherapy: biochemical recurrence defined as nadir PSA + 2 ng / ml
• Age ≥18 years
• Signing informed consent